( Info on latest on the subject)

Alzheimer’s disease (AD) research in 2025 highlights new insights and treatments. Over 7 million Americans and 55 million globally live with dementia, with AD causing 60–70% of cases. Research identifies “dark microglia” producing toxic lipids, linked to synapse loss, and dysfunctional ABCA1 protein in APOE4 gene carriers, increasing Alzheimer’s risk. RNA modification genes (MEPCE, HNRNPA2B1) are emerging drug targets. Therapies like Lecanemab and Donanemab, FDA-approved antibodies, clear amyloid plaques, slowing early AD. Remternetug shows 75% amyloid clearance, while E2814 and AADvac1 target tau aggregation. Sodium Oligomannate modulates the gut microbiome, and Semaglutide trials explore neuroprotection. Inflammation-focused drugs like INmune Bio’s target TNF-α. Costs may hit $2.8 trillion globally by 2030. APOE ε2 gene therapy and blood-based biomarkers for early diagnosis are advancing, with ongoing trials expected to yield results by 2025–2027, offering hope for better management.
Regards,
JAKSTAR PHARMA.